Silvio Danese, MD, PhD

Humanitas Clinical and Research Center
Rozzano Italy
Biographical Sketch: Silvio Danese is a Gastroenterologist at the Istituto Clinico Humanitas in Milan, which is related to the University of Milan, Italy. He is Head of the Inflammatory Bowel Disease (IBD) Center in the Division of Gastroenterology. Dr Danese trained in Gastroenterology at Policlinico Gemelli, Rome and graduated as a PhD, working from 2001 to 2004 in Dr Claudio Fiocchi’s laboratory at the Case Western Reserve University, Cleveland, Ohio, USA.

Dr Danese’s main research area of interest is the investigation of the fundamental mechanisms underlying IBD pathogenesis, while his daily clinical activity is related to IBD outpatient service. He is actively involved in many international clinical trials in IBD-related areas and has published more than 100 papers in several journals, including Gastroenterology, Gut, Journal of Clinical Investigation, Nature and Journal of Immunology.

Dr Danese is a member of many organisations related to the IBD field, including the European Crohn´s and Colitis Organization (ECCO), where he served as Secretary from 2012 to 2015, and the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD), where he serves as Scientific Secretary. He also sits on the Editorial Board of Gut and Alimentary Pharmacology and Therapeutics.

Any personal financial relationships? No

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

To the best of my ability, I will ensure that any speakers or content I suggest is independent of commercial bias.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 01/31/2015 by SILVIO DANESE

Papers:
New Therapies for IBD: From the Bench to the Bedside

	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
	To the best of my ability, I will ensure that any speakers or content I suggest is independent of commercial bias.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".